Clinical Trial Update: Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and tolerability of orally administered DF-003 in ROSAH syndrome patients; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rosah Syndrome

Drugs mentioned

• DF-003

Snippet

Sponsor: Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) | Conditions: ROSAH | Phase 1 | Status: RECRUITING